Incyte Co. (NASDAQ:INCY) Shares Bought by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC grew its holdings in Incyte Co. (NASDAQ:INCY) by 6.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,553 shares of the biopharmaceutical company’s stock after purchasing an additional 1,434 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Incyte were worth $1,486,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Dimensional Fund Advisors LP boosted its stake in Incyte by 7.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 950,626 shares of the biopharmaceutical company’s stock worth $59,689,000 after buying an additional 62,380 shares during the period. Quadrant Capital Group LLC boosted its position in shares of Incyte by 85.2% during the 4th quarter. Quadrant Capital Group LLC now owns 711 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 327 shares during the period. UBS Group AG increased its holdings in Incyte by 32.8% in the 4th quarter. UBS Group AG now owns 522,071 shares of the biopharmaceutical company’s stock valued at $32,781,000 after purchasing an additional 128,859 shares during the last quarter. D.A. Davidson & CO. purchased a new stake in Incyte in the fourth quarter valued at approximately $265,000. Finally, Corient Private Wealth LLC lifted its stake in Incyte by 55.9% during the fourth quarter. Corient Private Wealth LLC now owns 8,546 shares of the biopharmaceutical company’s stock worth $537,000 after purchasing an additional 3,065 shares in the last quarter. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Barry P. Flannelly sold 1,306 shares of the company’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $64.19, for a total value of $83,832.14. Following the completion of the sale, the executive vice president now directly owns 58,042 shares of the company’s stock, valued at approximately $3,725,715.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Incyte news, EVP Barry P. Flannelly sold 8,148 shares of Incyte stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $60.00, for a total value of $488,880.00. Following the transaction, the executive vice president now directly owns 50,534 shares in the company, valued at $3,032,040. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Barry P. Flannelly sold 1,306 shares of the stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $64.19, for a total transaction of $83,832.14. Following the sale, the executive vice president now owns 58,042 shares of the company’s stock, valued at approximately $3,725,715.98. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,047 shares of company stock valued at $2,225,626. 17.50% of the stock is currently owned by insiders.

Incyte Stock Performance

Shares of Incyte stock opened at $65.74 on Friday. The company has a quick ratio of 1.84, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. Incyte Co. has a 52 week low of $50.27 and a 52 week high of $70.36. The firm’s 50 day moving average is $64.37 and its two-hundred day moving average is $59.80. The firm has a market capitalization of $14.76 billion, a P/E ratio of 19.92, a P/E/G ratio of 5.03 and a beta of 0.73.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60). Incyte had a net margin of 2.52% and a return on equity of 0.75%. The company had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same period last year, the business earned $0.77 earnings per share. The company’s quarterly revenue was up 9.3% on a year-over-year basis. Research analysts forecast that Incyte Co. will post 0.67 EPS for the current fiscal year.

Analyst Ratings Changes

INCY has been the topic of several research analyst reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a report on Monday, September 16th. Royal Bank of Canada reiterated a “sector perform” rating and set a $67.00 price target on shares of Incyte in a research note on Tuesday, September 3rd. Citigroup raised their price objective on shares of Incyte from $80.00 to $88.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Truist Financial reaffirmed a “hold” rating and set a $74.00 target price (down from $83.00) on shares of Incyte in a research note on Wednesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Incyte from $59.00 to $61.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $73.24.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.